Business Context and Reporting Period
This Form 8-K is a current report filed by NanoVibronix, Inc. (trading symbol: NAOV) on August 29, 2023. The filing addresses a specific regulatory event rather than a standard financial reporting period. The company is incorporated in Delaware and its common stock is listed on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory disclosure and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the Company's response to a payment determination issued by the Centers for Medicare & Medicaid Services (CMS) regarding its PainShield device. The Company issued a press release on August 29, 2023, detailing this response, which is furnished as Exhibit 99.1 to this report.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlooks, or a discussion of general risks. The primary focus is the regulatory interaction with CMS. The Company explicitly states it undertakes no obligation to update, supplement, or amend the materials attached to this report. The information is furnished pursuant to Item 7.01 (Regulation FD Disclosure) and is not deemed filed for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 29, 2023) for the full details of the Company's response to the CMS payment determination.
- Verify the impact of the CMS payment determination on the commercial viability of the PainShield device.
- Check subsequent filings for any updates regarding the CMS decision, as the Company has disclaimed an obligation to update this specific 8-K.
- Confirm the current trading status of NAOV on the Nasdaq Capital Market.